On the table are Acorda’s multiple sclerosis therapy Ampyra/Fampyra (dalfampridine) and Inbrija (levodopa inhalation powder) for Parkinson’s disease, which made sales of $45 million and $25 ...

Over the past decade, Acorda saw success with its drugs for neurological disorders. Inbrija (levodopa inhalation powder) and Ampyra (dalfampridine) — also marketed as Fampyra (fampridine ...